PROTÉINE LRRC8A DE CANAL ANIONIQUE RÉGULÉ PAR LE VOLUME DESTINÉE À ÊTRE UTILISÉE DANS LA MODIFICATION DE LA DIFFÉRENCIATION DES KÉRATINOCYTES ÉPIDERMIQUES

• 收藏
• 分享

专利权人:

B.R.A.I.N. BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AG

发明人:

ERTONGUR-FAUTH, Torsten,TROTHE, Janina,BÜRGER, Claudia

申请号：

EPEP2019/053820

公开号：

WO2019/158696A1

申请日:

2019.02.15

申请国别(地区):

EP

年份:

2019

代理人:

摘要：

The present invention relates to the leucine-rich repeat-containing protein 8A (LRRC8A), and/or an activator of LRRC8A, for use in the treatment and/or prevention of a skin condition associated with an altered differentiation of keratinocytes. Preferably, the skin condition associated with an altered differentiation of keratinocytes is psoriasis or dermatitis, preferably atopic dermatitis. The present invention further relates to a method of identifying a compound capable of altering the differentiation of keratinocytes, the method comprising the steps of (a) contacting keratinocytes with a test compound and determining the amount of LRRC8A protein or LRRC8A transcript in said keratinocytes； and (b) comparing the amount of LRRC8A protein or LRRC8A transcript determined in step (a) with the amount of LRRC8A protein or LRRC8A transcript in a control not contacted with said test compound, wherein a change in the amount of LRRC8A protein or LRRC8A transcript after contacting the keratinocytes with the test compound indicates that the test compound is capable of altering the differentiation of keratinocytes. Furthermore, the present invention relates to a method of identifying a compound capable of altering the differentiation of keratinocytes, the method comprising the steps of (a) contacting keratinocytes with a test compound and determining the activity of (a) VRAC(s) comprising LRRC8A in said keratinocytes； and (b) comparing the activity determined in step (a) with the activity in a control not contacted with said test compound, wherein a change in the activity of (a) VRAC(s) comprising LRRC8A after contacting the keratinocytes with the test compound indicates that the test compound is capable of altering the differentiation of keratinocytes. The present invention further relates to an inhibitor of the leucine-rich repeat-containing protein 8A (LRRC8A) for use in the treatment and/or prevention of a skin condition selected from skin injury and impaired wound healing,

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/